New drug combo targets tough lung cancer mutation
NCT ID NCT03170206
First seen Feb 20, 2026 · Last updated May 22, 2026 · Updated 14 times
Summary
This early-phase study tested two drugs, palbociclib and binimetinib, in 34 people with advanced lung cancer that has a specific KRAS gene change. The main goal was to find the safest dose and see if the combination can shrink tumors or slow cancer growth. Participants had to have tried other treatments first, and the study focused on safety and how long the cancer stayed under control.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
Conditions
Explore the condition pages connected to this study.